Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Enspryng

- PMLiVE

Roche announces phase 3 results for KRAS G12C-mutated non-small cell lung cancer

The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care

- PMLiVE

Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS

If approved, this treatment would offer a new option for the nearly one million Americans living with MS

- PMLiVE

Roche and Dualitas Therapeutics announce research collaboration worth up to $1bn

The two companies aim to discover and develop novel bispecific antibodies for immunology and inflammation diseases

- PMLiVE

Roche’s Enspryng gets FDA Priority Review for autoimmune disease with no approved treatments

MOGAD, a rare disease of the central nervous system, can attack optic nerves, the spinal cord and the brain

- PMLiVE

Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment

This is the first and only at-home subcutaneous treatment option for this disease

- PMLiVE

Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer

Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years

- PMLiVE

Roche and Nurix Therapeutics to partner in $2.3bn deal

The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology

- PMLiVE

Roche opens new Swiss Institute of Human Biology research facility

The new building is part of a 1.5bn euro site investment

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Datroway given FDA Priority Review for breast cancer treatment

Approximately 70% of metastatic triple-negative breast cancer patients are ineligible for immunotherapy, creating an unmet medical need

- PMLiVE

Roche’s Columvi improves survival in large B-cell lymphoma

Approximately 160,000 people are diagnosed with this aggressive form of cancer each year

- PMLiVE

Roche receives FDA clearance for whooping cough test

There are around 24.1 million cases of whooping cough annually, with around 170,000 deaths

- PMLiVE

Genentech announces positive clinical results for BTK inhibitor MS treatment

Multiple sclerosis affects more than 2.9 million people globally

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links